Emavusertib Progresses to Phase 2 Study in AML and MDS
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.
Source: onclive.com
Stay updated with breaking news from Erics Winer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.